Multiple-Dose Pharmacokinetics in Serum and Sputum of Sagamicin Administered Intramuscularly to Patients

Abstract

Sagamicin is an aminoglycosidic antibiotic produced by Micromonospora sagamiensis, chemically related with gentamicin. Single- and multiple-dose pharmacokinetics have been investigated in patients affected by bronchopulmonary infections treated with 60 mg sagamicin i.m. every 12 h. The two concentration-time curves for sputum and serum are parallel; while there is no evidence of accumulation in the serum at the 7th day of treatment, sagamicin concentrations in the sputum are significantly higher on the 7th day, and this is also confirmed by a remarkable difference between the two AUC values. The good penetration power of sagamicin into sputum makes this antibiotic useful for the treatment of infections of the respiratory tract.

Complexation equilibria of ambroxol hydrochloride in solution by potentiometric and conductometric methods

“…AMB is often used in adjuvant therapy of chronic obstructive pulmonary disease and other chronic respiratory disorders [1][2][3]. It increases the production of surfactant by type II pneumocytes [4], accelerates the maturation of fetal lung [5], and therefore has also been used in the treatment of infant respiratory distress syndrome [6]. It is officially reported in British Pharmacopeia [7] and Indian Pharmacopeia [8].…”